[{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Wize Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bonus BioGroup","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Bonus BioGroup \/ Bonus BioGroup","highestDevelopmentStatusID":"12","companyTruncated":"Bonus BioGroup \/ Bonus BioGroup"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Activated mesenchymal stromal cells","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Not Applicable"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Activated mesenchymal stromal cells","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Not Applicable"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"MesenCure","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bonus BioGroup

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Treatment with MesenCure reduced fluid in the lungs by 47% compared to untreated subjects, and significantly increased blood lymphocyte counts, which play a key role in fighting viruses.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 27, 2020

                          Lead Product(s) : MesenCure

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Bonus reported that following treatment with MesenCure, the microscopic appearance of treated lungs was similar to healthy lungs, and a significant improvement in additional parameters was achieved.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 18, 2020

                          Lead Product(s) : Activated mesenchymal stromal cells

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Bonus BioGroup's mesenchymal stromal cell (MSC)-based drug MesenCure intended to treat acute respiratory distress resulting from COVID-19 and other causes.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          April 21, 2020

                          Lead Product(s) : Activated mesenchymal stromal cells

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 16, 2020

                          Lead Product(s) : Sodium Hyaluronate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Recipient : Wize Pharma

                          Deal Size : $7.4 million

                          Deal Type : Agreement

                          blank